(Q28341572)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1237376

4 September 2022

M. Kremer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1237376

4 September 2022

J. Abbosh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1237376

4 September 2022

V. E. Jones

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1237376

4 September 2022

S. Knight

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1237376

4 September 2022

P. B. Medawar

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1237376

full work available at URL

4 September 2022

language of work or name

English

0 references

publication date

July 1975

0 references

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/1237376/?tool=EBI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1237376

Clinical and Experimental Immunology

4 September 2022

published in

0 references

volume

21

0 references

issue

1

0 references

page(s)

1-12

0 references

cites work

The use of specific "lymphocyte" antisera to inhibit hypersensitive reactions of the "delayed" type

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Effect of 'maximum immune suppression' with thoracic duct drainage, ALG, azathioprine and cortisone in some neurological disorders

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Long-term treatment of multiple sclerosis with azathioprine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

The selective action of antilymphocyte serum on recirculating lymphocytes: a review of the evidence and alternatives

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

<i>In vitro</i> Delayed (Cellular) Hypersensitivity in Multiple Sclerosis to Central Nervous System Antigens

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Immunological tolerance induced in adult dogs by small amounts of horse IgG.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Effects of cortisol and antilymphocyte serum on lymphoid populations.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Multiple sclerosis: a review.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Failure of antilymphocytic globulin therapy in chronic progressive multiple sclerosis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Intensive immunosuppression in patients with disseminated sclerosis. III. Lymphocyte response in vitro

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

A tissue-culture approach to demyelinative disorders.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Intensive immunosuppression in the treatment of multiple sclerosis.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1538239

Intensive immunosuppression in patients with disseminated sclerosis. II. Tolerance to equine IgG and effect on immunoglobulin and complement levels

27 November 2018

1 reference

12 December 2020

Therapeutic trial of Imuran (azathioprine) in multiple sclerosis

1 reference

12 December 2020

The treatment of multiple sclerosis

1 reference

12 December 2020

Therapeutic trial of immunosuppressive agents in multiple sclerosis

1 reference

12 December 2020

[Destruction of nerve cells cultured "in vitro" by lymphocytes from patients with multiple sclerosis. Auto-immune pathogenesis of multiple sclerosis]

1 reference

12 December 2020